Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira, a leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for approximately USbn. The Boards of Directors of both companies have unanimously approved the merger. 'Hospira’s business aligns well with our new commercial structure and is an excellent strategic fit for our Global Established Pharmaceutical (GEP) business, which will benefit ...